Volta Medical, a pioneering health tech company focused on AI-powered cardiac care, has announced a major update to the U.S. labeling of its flagship product, Volta AF-Xplorer.
As first reported by MedTech Insights, this update now incorporates clinical evidence from the TAILORED-AF trial—an important validation of the system’s efficacy in treating persistent atrial fibrillation (AF), a particularly complex and underserved subset of AF cases. The AI-driven system assists electrophysiologists with real-time, data-informed decisions during catheter ablation procedures.
Source: volta-medical.us.
TAILORED-AF Trial: Setting a New Standard
The TAILORED-AF trial, a multicenter, randomized controlled study, compared outcomes between standard pulmonary vein isolation and Volta’s AI-guided tailored ablation. Results showed that 88% of patients in the AI-guided group remained AF-free after 12 months, compared to only 70% in the standard treatment group. These results, published in Nature Medicine, mark a historic first in electrophysiology—making Volta AF-Xplorer the only system to show level one evidence of superior long-term outcomes for persistent AF patients.
Addressing an Unmet Clinical Need
Persistent AF, which accounts for 75% of all AF cases, remains notoriously difficult to treat. Yet, only one-third of catheter ablations are currently performed for this advanced condition, leaving many patients to endure ongoing symptoms. Volta’s innovation aims to shift that paradigm by offering physicians a validated, AI-driven approach to treating these high-risk patients more effectively.
Empowering Physicians, Improving Lives
According to Volta Medical’s CEO, Theophile Mohr Durdez, this label expansion signifies a transformative moment for both the company and the broader electrophysiology community. The AF-Xplorer system empowers physicians to make more precise and individualized treatment decisions, potentially improving the quality of life for millions who suffer from persistent AF.
The U.S. labeling expansion for Volta AF-Xplorer, backed by strong clinical evidence from the TAILORED-AF trial, not only reaffirms the promise of AI in cardiac care but also provides new hope for persistent AF patients. This milestone cements Volta Medical’s position at the forefront of AI-guided medical innovation, reshaping how one of the most challenging heart conditions is treated.
